^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastric Adenocarcinoma

    Related cancers:
    1d
    RAGIP: Recurrence After Gastric and Intestinal Polyp Resection (clinicaltrials.gov)
    P=N/A, N=2000, Not yet recruiting, LanZhou University | Initiation date: Jan 2026 --> Jul 2026
    Trial initiation date
    1d
    Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (clinicaltrials.gov)
    P2, N=54, Completed, Hospices Civils de Lyon | Unknown status --> Completed | Trial completion date: Oct 2023 --> Jun 2026 | Trial primary completion date: Oct 2023 --> Jun 2026
    Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • ipatasertib (RG7440)
    1d
    How to Define the Gastroesophageal Junction. (PubMed, Dig Endosc)
    Furthermore, we will briefly discuss endoscopic treatment, chemotherapy, and surgical treatment for GEJ cancer. Looking ahead, the reclassification of GEJ cancers using the Kyoto international consensus, coupled with comprehensive molecular analyses of tumors, promises to yield valuable insights.
    Review • Journal
    |
    CDX2 (Caudal Type Homeobox 2)
    1d
    Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=52, Recruiting, Qilu Hospital of Shandong University
    New trial • HEOR
    5d
    Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer (clinicaltrials.gov)
    P2, N=26, Completed, Samsung Medical Center | Recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab)
    5d
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Apr 2026 --> Sep 2026
    Trial initiation date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    5d
    Practical guidelines for multiple instance learning in computational pathology: how embedding choice impacts overall survival prediction. (PubMed, Front Bioinform)
    Our results show that embedding choice has a substantial and consistent impact on OS prediction accuracy, robustness, and interpretability across cancer types, with domain-specific and foundation models outperforming conventional convolutional baselines. These findings provide evidence-based practical guidelines for designing robust and generalizable WSI-based survival prediction pipelines in computational pathology.
    Journal • BRCA Biomarker
    |
    BRCA (Breast cancer early onset)
    6d
    MMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=3000, Not yet recruiting, Shanghai Zhongshan Hospital
    New trial • Mismatch repair
    7d
    BNIHGC: Beta-Blockers on Neoadjuvant Immunochemotherapy for Hypertensive Patients With Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=80, Active, not recruiting, Nanfang Hospital, Southern Medical University
    New trial
    7d
    Case Report: gastric signet-ring-cell adenocarcinoma in a young adult with tracheoesophageal fistula/esophageal atresia and complex gastrointestinal history. (PubMed, Front Oncol)
    This case highlights the interplay of congenital foregut anomalies, chronic inflammation, and SRC development, and underscores the critical importance of meticulous biopsy handling and personalized endoscopic care. Tailored surveillance may be appropriate in select early-stage SRC cases where localization is uncertain and imaging is negative.
    Journal
    |
    TP53 (Tumor protein P53) • MLH1 (MutL homolog 1) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • CDH1 (Cadherin 1) • CTNNA1 (Catenin Alpha 1)
    7d
    Claudin 18.2 Expression in Gastric Adenocarcinoma: Diagnostic Reproducibility and Clinicopathologic Associations in A Western Cohort. (PubMed, Oncol Res)
    Background: Claudin 18.2 (CLDN18.2) has become a clinically relevant therapeutic target in gastric adenocarcinoma (GC), with zolbetuximab now approved for use in CLDN18.2-positive, HER2-negative advanced disease... CLDN18.2 shows excellent intratumoral reproducibility and a stable biological profile in GC, supporting its diagnostic reliability in biopsies and value as a predictive biomarker. A subset with extreme expression demonstrated aggressive features, suggesting a potential "claudin-driven" phenotype requiring further study.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18) • CDH1 (Cadherin 1)
    |
    HER-2 negative • CLDN18.2 expression • CLDN18.2 positive
    |
    Vyloy (zolbetuximab-clzb)
    8d
    IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=90, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)